Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 6/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037693 | 0.96 | CTSL (0.57) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL16323443 | 0.96 | CTSL (0.57) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL16323306 | 0.96 | CTSL (0.57) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL16322478 | 0.96 | CTSL (0.57) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL6272041 | 0.90 | CTSL (0.55) | CASP1CTSLCTSBCTSSCTSK | |
| SCHEMBL16321202 | 0.87 | CAPN1 (0.58) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL1038643 | 0.87 | CAPN1 (0.58) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL9556498 | 0.87 | CAPN1 (0.58) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL16322884 | 0.87 | CAPN1 (0.58) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL16322231 | 0.87 | CAPN1 (0.58) | CTSLCTSBCTSSCTSKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2237793-A1 | INHIBITORS OF CATHEPSIN B | Virobay, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009100225-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | CTSB, CSTB, CTSF | CASP1 690/4885CTSL 12/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.